Dr. Paymohn Mahdavi, M.D.
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
1845 W Redlands Blvd Ste 101
Redlands, CA 92373
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York Medical College (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 16
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: New York Medical College
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
CA license A162708 (first issued 2019; current) -
Ophthalmology Physician
CA license A162708 (first issued 2019; current) · MD license D0083614
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Azul Vision Inc (48 clinicians)
- California Eye Specialists Medical Group Inc (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 16
- Services billed
- 154
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 3,240 | 16 |
| Imaging of retina | 1,276 | 519 |
| Established patient office or other outpatient visit, 20-29 minutes | 868 | 388 |
| Injection, aflibercept, 1 mg | 865 | 94 |
| Injection of drug into eye | 607 | 144 |
| Established patient office or other outpatient visit, 30-39 minutes | 424 | 270 |
| Extended exam of the back part of the eye with retinal drawing | 183 | 140 |
| Injection, bevacizumab, 10 mg | 143 | 43 |
| New patient office or other outpatient visit, 45-59 minutes | 86 | 86 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 34 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Redlands, CA | 760 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Redlands, CA | 528 |
| Latanoprost Other prescribers in Redlands, CA | 435 |
| Ketorolac Tromethamine Other prescribers in Redlands, CA | 281 |
| Bromfenac Sodium | 187 |
| Brimonidine Tartrate Other prescribers in Redlands, CA | 157 |
| Dorzolamide Hcl Other prescribers in Redlands, CA | 82 |
| Timolol Maleate Other prescribers in Redlands, CA | 75 |
| Ofloxacin Other prescribers in Redlands, CA | 49 |
| Atropine Sulfate | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $153 in total to this clinician.
| Mallinckrodt Hospital Products Inc. | $51.89 |
|---|---|
| Ani Pharmaceuticals, Inc. | $43.63 |
| Genentech USA, Inc. | $24.66 |
| Amgen Inc. | $17.94 |
| Thea Pharma Inc. | $14.40 |
| Food and Beverage | $153 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $14,468 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.